[Okayama University] Rebooting Dormant Abilities with 'Pseudo-Hypoxia' ~Simultaneous Awakening of Immunity and Repair Power Driven by Iron Mobilizing Chelators~
Okayama University elucidates the mechanism by which iron chelators induce 'pseudo-hypoxia,' simultaneously awakening immunity and repair capabilities.
📋 Article Processing Timeline
- 📰 Published: March 30, 2026 at 07:43
- 🔍 Collected: March 30, 2026 at 09:00 (1h 17m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 10:03 (385h 2m after Collected)
Press release on joint research results from Okayama University and Toyama University.
March 29, 2026
National University Corporation Okayama University
<Key Points of the Announcement>
We have elucidated the molecular mechanism by which specific 'iron mobilizing iron chelators' block the function of cellular oxygen sensor enzymes, inducing a state of 'functional pseudo-hypoxia' where cells mistakenly perceive a lack of oxygen even in an environment with sufficient oxygen.
When this 'false hypoxia alarm' sounds, the cell's emergency switch is turned on, simultaneously releasing and rebooting the body's own powerful 'immunity (anti-tumor effects)' and 'tissue repair capabilities (nerve regeneration)' that were previously dormant.
This method has shown potential to improve the therapeutic effects for colorectal and lung cancers, which are resistant to existing immunotherapies. Furthermore, in aged mouse models, it has demonstrated the possibility of suppressing the decline in cognitive function (working memory) without causing inflammation in the brain. This holds promise as a completely new platform therapeutic concept for intractable diseases.
◆Overview
A joint research team, including Associate Professor Toshiaki Ohara and Professor Akihiro Matsukawa from the Department of Pathology (Immunopathology), Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University; Lecturer Kazuhiro Noma from the Department of Clinical Medicine (Gastroenterological Surgery), Faculty of Medicine; Associate Professor Hodaka Kawai from the Department of Oral Pathology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University; Professor Yoshiaki Iwasaki from the Department of Management of Research and Educational Development, Okayama University; Professor Toru Yamashita from the Department of Neurology, Faculty of Medicine, Toyama University; and Associate Professor Tomonari Kasai from the Department of Applied Chemistry, Graduate School of Engineering, Nagoya University, has revealed that by artificially inducing 'functional pseudo-hypoxia' using iron mobilizing iron chelators, the dormant immune and repair capabilities within the body can be dramatically enhanced, leading to the augmentation of anti-tumor immune responses against cancer and the suppression of cognitive decline.
The research team orally administered iron mobilizing iron chelators (such as Roxadustat and SP10) to mouse models of colorectal and lung cancer to induce pseudo-hypoxia.
As a result, the secretion of a key cytokine that activates immune cells (IL-2) was promoted, and the efficacy of existing immune checkpoint inhibitors (anti-PD-1 antibody) was synergistically enhanced.
Furthermore, when the same method was applied to aged mice, it was confirmed that nerve regeneration signals were selectively activated without causing harmful inflammation in the brain, suppressing the decline in working memory associated with aging.
The utilization of the new concept of 'functional pseudo-hypoxia' has the potential to develop into next-generation innovative therapies for intractable modern diseases such as cancer and dementia, not by attacking the diseases from the outside, but by maximizing the inherent strengths of the body to confront them.
These findings have been published in three international academic journals.
This information was released by Okayama University on March 26, 2026.
FAQ
What is 'functional pseudo-hypoxia'?
Functional pseudo-hypoxia is a state where cells mistakenly perceive a lack of oxygen, even when sufficient oxygen is present. This is induced by blocking the function of cellular oxygen sensor enzymes, often through the use of specific iron chelators.
How does inducing pseudo-hypoxia help the body?
When cells sense 'pseudo-hypoxia,' it triggers an emergency response. This response activates the body's dormant immune capabilities, such as anti-tumor effects, and repair mechanisms, like nerve regeneration, effectively rebooting these functions.
What types of diseases could this new approach potentially treat?
This approach shows promise for treating difficult diseases such as colorectal cancer, lung cancer, and age-related cognitive decline (like memory loss) without causing harmful inflammation.
What are iron mobilizing iron chelators?
These are specific types of compounds that interact with iron in the body. In this research, they are used to block oxygen sensor enzymes, thereby inducing the pseudo-hypoxia state. Examples mentioned include Roxadustat and SP10.
What is the significance of this research for future medicine?
This research introduces a novel therapeutic concept that leverages the body's own latent abilities rather than solely relying on external interventions. It could lead to a new generation of treatments for intractable diseases by enhancing natural immunity and repair functions.
What is the relationship between this research and existing cancer treatments?
The study found that inducing pseudo-hypoxia can synergistically enhance the effectiveness of existing immunotherapies, such as immune checkpoint inhibitors (anti-PD-1 antibodies), for cancers like colorectal and lung cancer.
Can this method help with aging-related cognitive decline?
Yes, the research demonstrated that applying this method to aged mice suppressed the decline in working memory associated with aging, and importantly, did so without causing inflammation in the brain.